A special issue of the European Journal of Cancer presents detailed reports on the wide range of research presented during the 1st EORTC Cancer Survivorship Summit held this past January in Brussels, Belgium.
Early diagnosis, targeted therapeutics, and more personalized multimodal treatments has boosted survival rates of patients with cancer and led to a large and rapidly increasing number of cancer survivors. Despite this good news, cancer survivors are often confronted with a broad spectrum of late adverse treatment effects and some must also deal with societal discrimination due to slower performance, chronic fatigue or partial inability. Such things can adversely affect employment, education, insurance or mortgage opportunities.
In January 2014, the 1st EORTC Cancer Survivorship Summit was organized to facilitate interaction between clinicians, researchers, social workers, patients, insurers, bankers and policy makers. A special issue of the European Journal of Cancer is entirely dedicated to the research presented at this Summit and addresses, respectively, second malignancies, cardiovascular disease, cognitive dysfunction, infertility/sexuality and psycho-social problems following cancer treatment.